Which organizations are lobbying on the active drug pricing bills in the 119th Congress, and what coalition or side is each on?

Senate LDA filings do not disclose positions (support/oppose) — only the organizations that filed and the bills they mentioned. Based on the 2,358 drug pricing lobbying filings from 2025–2026 Q3, here's the landscape:

Top Lobbying Organizations (by filing count)

Pharmaceutical Manufacturers & Industry Groups:

• Pharmaceutical Research and Manufacturers of America (PhRMA): 92 filings
• Amgen: 30 filings (outside firm representation)
• Gilead Sciences: 27 filings
• Genentech: 25 filings (outside firm)
• Novartis: 24 filings
• Bristol-Myers Squibb: 20 filings
• Pfizer: 20 filings
• Eli Lilly: 18 filings
• Biotechnology Innovation Organization (BIO): 18 filings
• Vertex Pharmaceuticals: 17 filings

Healthcare Access & Specialty Medicine:

• 340B Health: 26 filings (hospital and health system coalition focused on the 340B drug discount program)
• Grifols Shared Services: 5 filings (plasma-derived therapies)
• University of Pittsburgh Medical Center: 15 filings

Health Insurance & Payers:

• America's Health Insurance Plans (AHIP): Largest disclosed lobbying spender at $23.74 million in expenses across multiple filings mentioning drug pricing bills

Bills with Most Lobbying Activity

The most-lobbied drug pricing bills in the 119th Congress are:

1. H.R. 1492 — Equalize negotiation period for small-molecule and biologic drugs: 196 filings, 35 clients
2. H.R. 946 — Optimizing Research Progress Hope And New Cures Act: 145 filings, 38 clients
3. S. 832 — Ensuring Pathways to Innovative Cures Act: 106 filings, 22 clients
4. H.R. 4299 — Protecting Patient Access to Cancer and Complex Therapies Act: 78 filings, 26 clients

Key Limitation

LDA filings do not state positions. The 2,358 filings show which organizations are active on drug pricing, but Senate lobbying disclosures do not require filers to disclose whether they support or oppose specific bills. The filing text sometimes includes general policy positions (e.g., "generally opposing the imposition of price controls" or "generally supporting intellectual property rights"), but these are broad policy stances, not bill-specific positions. To determine actual coalitions and sides, you would need to cross-reference press releases, hearing testimony, or other public statements from these organizations.

Sources:

• S. 1818 (Prescription Drug Price Relief Act)
• H.R. 3546 (Prescription Drug Price Relief Act)
• S. 1587 (Fair Prescription Drug Prices for Americans Act)